i3 Clinical Trials Report

CTR-COVID-19

The cataclysm caused by the COVID-19 pandemic has impacted on clinical trials in terms of alternatives for study participants, enhanced operational and financial support for progressively more complex trial protocol designs and greater collaboration among sponsors.

Therefore, presented here is a sample of the summarised report of new candidate antiviral and vaccine therapies undergoing clinical trials worldwide as from the week 4 to 8 May 2020 in the pursuit of gaining regulatory approval for treatment and/or prophylaxis against SARS-CoV-2 coronavirus infection.

To purchase the full report visit our i3 Shop.

Legal Disclaimer: All content given in this report is for informational purposes only and does not constitute clinical or financial advice. The publisher does not make any guarantee as to any results that may be obtained from using our content. To the maximum extent permitted by law, the publisher disclaims any and all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations prove to be inaccurate, incomplete or unreliable, or result in any health-related mis-treatment, adverse event or financial investment or other losses. Your use of the information contained in this report is at your own risk.

Click here to see our Previous Clinical Trial Reports.